Compare Stocks → [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABIONASDAQ:ACHVNASDAQ:AKEROTCMKTS:GNWSDOTCMKTS:GNWSF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABIOARCA biopharma$3.45+1.5%$2.11$1.56▼$3.88$50.03M1.171.16 million shs294,919 shsACHVAchieve Life Sciences$4.41-2.2%$4.41$3.03▼$10.30$154.48M1.3271,487 shs82,081 shsAKERAkers Biosciences$2.58+3.2%$3.56$1.65▼$6.97$42.97M0.3769,876 shs64,695 shsGNWSDStageZero Life Sciences$0.03$0.03$0.17▼$0.89$1.32M2.974,987 shsN/AGNWSFStageZero Life Sciences$0.03$0.03$0.00▼$1.27$1.70M0.2826,719 shsN/ABeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABIOARCA biopharma+1.47%+8.49%+94.92%+118.35%+77.84%ACHVAchieve Life Sciences-2.22%-0.90%-4.13%-4.75%-45.22%AKERAkers Biosciences+3.20%+13.66%-2.64%+1,285.61%+51.76%GNWSDStageZero Life Sciences0.00%-6.25%-18.43%-6.25%-57.35%GNWSFStageZero Life Sciences0.00%-6.25%-18.43%-6.25%-57.35%[Shocking] Elon Musk’s Plan To End Banks (Ad)Leaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. Click here now to get your copy.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABIOARCA biopharmaN/AN/AN/AN/AN/AN/AN/AN/AACHVAchieve Life Sciences1.5428 of 5 stars3.52.00.00.03.00.00.6AKERAkers BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AGNWSDStageZero Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AGNWSFStageZero Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABIOARCA biopharmaN/AN/AN/AN/AACHVAchieve Life Sciences3.00Buy$17.25291.16% UpsideAKERAkers BiosciencesN/AN/AN/AN/AGNWSDStageZero Life SciencesN/AN/AN/AN/AGNWSFStageZero Life SciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest ABIO, ACHV, GNWSD, AKER, and GNWSF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2024ACHVAchieve Life SciencesJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.004/1/2024ACHVAchieve Life SciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$18.003/5/2024ACHVAchieve Life SciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $11.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABIOARCA biopharmaN/AN/AN/AN/A$2.89 per shareN/AACHVAchieve Life SciencesN/AN/AN/AN/A($0.07) per shareN/AAKERAkers Biosciences$1.58M27.19N/AN/A$5.38 per share0.48GNWSDStageZero Life Sciences$140K9.44N/AN/A($0.13) per share-0.21GNWSFStageZero Life Sciences$4.15M0.41N/AN/A($0.02) per share-1.35Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABIOARCA biopharma-$5.34M-$0.37N/A∞N/AN/A-13.80%-13.33%N/AACHVAchieve Life Sciences-$29.82M-$1.53N/AN/AN/AN/A-936.70%-127.66%5/14/2024 (Estimated)AKERAkers Biosciences-$3.89MN/A0.00∞N/AN/A-87.42%-73.31%N/AGNWSDStageZero Life Sciences-$3.48MN/A0.00∞N/A217.39%N/A-61.21%N/AGNWSFStageZero Life Sciences-$6.86M-$0.28N/A∞N/A-200.26%N/A-165.13%N/ALatest ABIO, ACHV, GNWSD, AKER, and GNWSF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ACHVAchieve Life Sciences-$0.32-$0.26+$0.06-$0.26N/AN/A2/1/2024Q4 2023ABIOARCA biopharmaN/A-$0.08-$0.08-$0.08N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABIOARCA biopharmaN/AN/AN/AN/AN/AACHVAchieve Life SciencesN/AN/AN/AN/AN/AAKERAkers BiosciencesN/AN/AN/AN/AN/AGNWSDStageZero Life SciencesN/AN/AN/AN/AN/AGNWSFStageZero Life SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABIOARCA biopharmaN/A59.0159.01ACHVAchieve Life Sciences4.020.820.82AKERAkers BiosciencesN/A9.229.22GNWSDStageZero Life SciencesN/A0.090.06GNWSFStageZero Life SciencesN/A1.151.08OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABIOARCA biopharma56.44%ACHVAchieve Life Sciences33.52%AKERAkers Biosciences5.52%GNWSDStageZero Life SciencesN/AGNWSFStageZero Life Sciences0.02%Insider OwnershipCompanyInsider OwnershipABIOARCA biopharma30.90%ACHVAchieve Life Sciences2.00%AKERAkers Biosciences0.29%GNWSDStageZero Life SciencesN/AGNWSFStageZero Life SciencesN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABIOARCA biopharma414.50 million10.02 millionOptionableACHVAchieve Life Sciences2234.25 million33.57 millionOptionableAKERAkers Biosciences416.65 millionN/ANot OptionableGNWSDStageZero Life SciencesN/A48.94 millionN/ANot OptionableGNWSFStageZero Life Sciences5163.00 millionN/ANot OptionableABIO, ACHV, GNWSD, AKER, and GNWSF HeadlinesSourceHeadlineCommunity invited to learn about the life sciences, meet industry leaders, and tour facilities at Momentum Labsmsn.com - April 20 at 1:49 AMNew report shows sustained growth for Washington's life science industrybizjournals.com - April 19 at 10:47 AMStageZero Life Sciences: Top 10 Undervalued Healthcare Sector Stocks on TSX (SZLS)theglobeandmail.com - April 4 at 9:21 AMLife Below Zero Season 9 Streaming: Watch & Stream Online via Disney Plusmsn.com - March 5 at 7:32 AMArea life-science companies attract new attentionbizwest.com - February 22 at 1:12 AMWu awards $4.7 million to train Bostonians in life sciences industrybizjournals.com - February 15 at 3:20 PMThe Future of the Pro-Life Movement: Meet 6 Gen-Z Leadersdailysignal.com - February 6 at 9:32 PMWhat Is the Sandwich Generation? Here’s What You Need to Know About This Growing Cohortmsn.com - February 3 at 8:31 AMNew Facilities Place Houston Life Sciences ‘At The Cusp Of The Horizon’bisnow.com - February 3 at 8:31 AMThe top life sciences startups to watch this yearbiospace.com - January 3 at 9:38 AMStageZero Life Sciences, Ltd Announces Q3 2023 Financial Results and Operational Updatefinance.yahoo.com - November 15 at 7:59 AMUnchained Labs Hosts Life Sciences Summit 2023independentnews.com - October 27 at 2:52 PMIn life sciences, Boston continues to reign supremebizjournals.com - October 26 at 12:32 PMSingapore Science Park Launches New Life Sciences and Innovation Cluster Geneo, Welcoming a New Era of Innovation to the Citylbbonline.com - October 23 at 8:47 PMNew York City life-science market ranks among top 10 in countrybizjournals.com - October 5 at 1:51 PMSyneos Health replaces CEO with life sciences veteran Colin Shannon days after $7B deal closesbizjournals.com - October 3 at 1:44 PMSustainability, equipment upgrades, and digitalization: big priorities for global pharmaceuticals, life science global study findsmarkets.businessinsider.com - September 12 at 1:12 PMReport: Mass. life sciences grew in 'toughest times' in Worcester, Suffolk countiesmsn.com - September 11 at 3:27 PMOrlando Science Center: Trees, tanks help ‘Life’ exhibit take shapeorlandosentinel.com - July 21 at 11:28 AMCanadian Investment Regulatory Organization Trading Halt - SZLS.WTfinance.yahoo.com - June 29 at 2:07 PMStageZero Life Sciences, Ltd. Announces Temporary Repricing of Warrants Expiring in 2023 and 2024finance.yahoo.com - June 20 at 9:30 AMStageZero Life Sciences, Ltd. Special and Annual General Meeting Conference Callfinance.yahoo.com - June 5 at 5:53 PM5 innovators to watch in R.I.’s life sciences industrymsn.com - May 29 at 6:14 PMAtlanta’s Nascent Life Sciences Industry Getting A Big Boost, But Is It Enough?bisnow.com - May 25 at 1:04 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideJPMorgan Chase Falls 5% as Consumer Cracking Begins to ShowApril 12, 2024 9:00 AMView JPMorgan Chase Falls 5% as Consumer Cracking Begins to ShowAll Headlines Company DescriptionsARCA biopharmaNASDAQ:ABIOARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.Achieve Life SciencesNASDAQ:ACHVAchieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.Akers BiosciencesNASDAQ:AKERAkers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.StageZero Life SciencesOTCMKTS:GNWSDStageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K. Wayne Marshall in 1998 and is headquartered in Markham, Canada.StageZero Life SciencesOTCMKTS:GNWSFStageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
